The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Escobar, M
- Castaman, G
- Callaghan, M
- de Moerloose, P
- Ducore, J
- Hermans, C
- Journeycake, J
- Leissinger, C
- Luck, J
- Mahlangu, J
- Miesbach, W
- Mitha, IH
- Negrier, C
- Quon, D
- Recht, M
- Schved, JF
- Shapiro, AD
- Sidonio, R
- Srivastava, A
- Stasyshyn, O
- Vilchevska, KV
- Wang, M
- Young, G
- Alexander, WA
- Al-Sabbagh, A
- Bonzo, D
- Macie, C
- Wilkinson, TA
- Kessler, C
Grupos
Abstract
Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in haemophilia A or B patients with inhibitors (=12 years of age). We describe here the EB safety profile from the three prospective Phase 3 clinical trials performed to date.
Datos de la publicación
- ISSN/ISSNe:
- 1351-8216, 1365-2516
- Tipo:
- Article
- Páginas:
- 921-931
- DOI:
- 10.1111/hae.14419
- PubMed:
- 34636112
- Factor de Impacto:
- 1,449 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
HAEMOPHILIA WILEY
Citas Recibidas en Web of Science: 10
Documentos
- No hay documentos
Filiaciones
Keywords
- PERSEPT, SEVENFACT, eptacog beta, haemophilia, inhibitors, recombinant FVIIa, safety
Campos de Estudio
Cita
Escobar M,Castaman G,BOIX SB,Callaghan M,de Moerloose P,Ducore J,Hermans C,Journeycake J,Leissinger C,Luck J,Mahlangu J,Miesbach W,Mitha IH,Negrier C,Quon D,Recht M,Schved JF,Shapiro AD,Sidonio R,Srivastava A,Stasyshyn O,Vilchevska KV,Wang M,Young G,Alexander WA,Al A,Bonzo D,Macie C,Wilkinson TA,Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021. 27. (6):p. 921-931. IF:4,268. (2).
Portal de investigación